Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Sponsor: Verastem, Inc.
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Official title: A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-07-28
Completion Date
2028-12
Last Updated
2026-10-26
Healthy Volunteers
No
Conditions
Interventions
VS-7375
Taken by mouth
cetuximab
Intravenous infusion
panitumumab
Intravenous infusion
Cetuximab + mFOLFOX6
Intravenous infusion
Locations (30)
HonorHealth
Scottsdale, Arizona, United States
START Los Angeles
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Valkyrie Clinical Trials (contact for more locations)
Los Angeles, California, United States
BRCR - Coral Springs
Coral Springs, Florida, United States
BRCR - Tamarac
Tamarac, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Indiana University, Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
START Midwest
Grand Rapids, Michigan, United States
Washington University
St Louis, Missouri, United States
START New Jersey
East Brunswick, New Jersey, United States
Perlmutter Cancer Center at NYU Langone Health (contact for more locations)
New York, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Case Western, University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee, United States
START Dallas Fort Worth
Fort Worth, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah, United States
START Mountain Region
West Valley City, Utah, United States
UVA Comprehensive Cancer Center
Charlottesville, Virginia, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Virginia Mason Medical Center
Seattle, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States
Macquarie University Hospital
Macquarie Park, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Icon Cancer Centre Townsville
Hyde Park, Queensland, Australia
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, Australia
Icon Cancer Centre Adelaide
Kurralta Park, South Australia, Australia
Icon Cancer Centre Hobart
Hobart, Tasmania, Australia
Alfred Hospital
Melbourne, Victoria, Australia